Skip to main content

Advertisement

Table 1 Tumour characteristics of the breast cancer specimens

From: TGFβ isoforms and receptors mRNA expression in breast tumours: prognostic value and clinical implications

Cohorts TCGA TCGA-sub RT-qPCR Ivshina Schmidt Symmans Wang
N 520 59 71 249 200 298 286
Histological type
 Ductal 442 (85.0) 51 (86.4) 56 (78.9)
 Lobular 41 (7.9) 3 (5.1) 5 (7.0)
 Mixed and others 36 (6.9) 5 (8.5) 9 (12.7)
Tumour diameter
 ≤2.0 cm 133 (25.6) 20 (33.9) 39 (54.9) 126 (50.6) 112 (56.0)
 >2.0 cm 364 (70.0) 38 (64.4) 32 (45.1) 123 (49.4) 88 (44.0)
Regional lymph nodes
 Negative 253 (48.7) 25 (42.4) 34 (47.9) 159 (63.9) 200 (100) 175 (58.7) 286 (100)
 Positive 256 (49.2) 34 (57.6) 36 (50.7) 81 (32.5) 0 (0) 112 (37.6) 0 (0)
Distant metastasis
 Negative 491 (94.4) 57 (96.6)
 Positive 15 (2.9) 1 (1.7)
TNM stage
 I 89 (17.1) 13 (22.0)
 II 290 (55.8) 34 (57.6)
 III 110 (21.2) 11 (18.6)
 IV 14 (2.7) 1 (1.7)
Tumour grade
 Grade 1 7 (9.9) 68 (27.3) 29 (14.5)
 Grade 2 25 (35.2) 126 (50.6) 136 (68.0)
 Grade 3 36 (50.7) 55 (22.1) 35 (17.5)
ER status
 Negative 117 (22.5) 9 (15.3) 18 (25.4) 34 (13.7) 0 (0) 77 (26.9)
 Positive 396 (76.2) 48 (81.4) 52 (73.2) 211 (84.7) 298 (100) 209 (73.1)
PR status
 Negative 176 (33.8) 16 (27.1) 22 (31.0)
 Positive 336 (64.6) 41 (69.5) 48 (67.6)
HER2 status
 Negative 361 (69.4) 48 (81.4) 60 (84.5)
 Positive 101 (19.4) 10 (16.9) 10 (14.1)
Triple-negative
 True 72 (13.8) 7 (11.9) 11 (15.5)
 False 448 (86.2) 52 (89.1) 60 (84.5)
PAM50 subtype
 Basal-like 96 (18.5) 11 (18.6)
 HER2-enriched 58 (11.2) 4 (6.8)
 Luminal A 231 (44.4) 32 (54.2)
 Luminal B 127 (24.4) 12 (20.3)
 Normal-like 8 (1.5) 0 (0)
  1. Data are presented as the number of patients in each subgroup with percentage in the parentheses. Numbers may not sum to total (N) due to missing datadata